


EGFR kinase inhibitor 4

| | |
|--------------------|---|
| Cat. No.: | HY-162300 |
| CAS No.: | 2922402-05-7 |
| Molecular Formula: | C ₄₀ H ₃₄ N ₈ O ₄ |
| Molecular Weight: | 690.75 |
| Target: | EGFR |
| Pathway: | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | EGFR kinase inhibitor 4 (Compound 4) is a bivalent ATP-allosteric EGFR inhibitor (IC ₅₀ : 1.8 nM for mutant EGFR (LRTMCS)). EGFR kinase inhibitor 4 can be used for research of NSCLC ^[1] . |
| IC ₅₀ & Target | IC ₅₀ : 1.8 nM for mutant EGFR (LRTMCS) ^[1] |
| In Vitro | EGFR kinase inhibitor 4 (0-10 μM, 6 h) inhibits LRTM phosphorylation (pY1068) and downstream pERK and pAKT in the human NSCLC cell lines (H1975, H3255, HCC827 cells) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Wittlinger F, et al. Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors. Commun Chem. 2024 Feb 20;7(1):38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA